Financial Data and Key Metrics Changes - The company reported $74.9 million in revenue for Q4 2025, down from $120.8 million in Q4 2024, primarily due to the wind-down of migrant-related projects [15] - For the full year 2025, total revenue was $322.2 million compared to $616.6 million in 2024 [15] - Adjusted EBITDA loss for Q4 2025 was $11.3 million, compared to a profit of $1.1 million in Q4 2024 [16] - The adjusted gross margin for Q4 2025 was 32.5%, down from 33.5% in Q4 2024 [17] Business Line Data and Key Metrics Changes - Medical transportation services revenue increased to $50.2 million in Q4 2025 from $49.1 million in Q4 2024 [15] - Mobile Health revenue for Q4 2025 was $24.8 million, down from $71.8 million in Q4 2024, but non-migrant Mobile Health revenues increased by 47% [16] - SteadyMD generated $6.1 million in revenue for DocGo in Q4 2025, with full-year gross margins improving from approximately 30% to 37% [6][17] Market Data and Key Metrics Changes - The company saw strong growth in markets like New York, Texas, and Tennessee, contributing to revenue increases in medical transportation [16] - The number of assigned lives in the care gap closure program increased by 12% sequentially, from 1.3 million to over 1.45 million [10] Company Strategy and Development Direction - The company is focused on integrating SteadyMD into its mobile health offerings and aims to consolidate provider networks by the end of Q2 2026 [7] - The company plans to reduce cash outlay in 2026 as early markets mature and become self-sustaining, with a goal of achieving profitability in the second half of 2026 [11] - An efficiency innovation portfolio has been launched, expected to deliver $5-$6 million in savings in 2026 and $20-$24 million in 2027 [12] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the strong demand for services and top-line growth across volume metrics, despite challenges in achieving profitability [14] - The company anticipates a full-year adjusted EBITDA loss in the range of $5 million to $10 million for 2026, an improvement from previous guidance [24] - Management highlighted the importance of technology and automation in driving efficiency and reducing costs while maintaining high service levels [70] Other Important Information - The company has initiated a process to explore strategic alternatives aimed at maximizing shareholder value [13] - Cash and cash equivalents at year-end were $68.3 million, down from $95.2 million, primarily due to the acquisition of SteadyMD and delays in collecting migrant-related accounts receivable [21][22] Q&A Session Summary Question: Can you provide details on the strategic alternatives process? - The company has engaged an investment bank to run a formal process aimed at maximizing shareholder value, but cannot share further details at this time [26] Question: What are the components driving the increased 2026 guidance? - The increase in revenue guidance is primarily driven by improved volumes in the Medical Transportation segment and additional upside from SteadyMD [28] Question: Can you quantify the free cash flow pressures in 2026? - The company expects cash balance to be lower due to working capital requirements and ongoing operating losses, but anticipates collecting outstanding receivables [33][36] Question: What is the outlook for the payer business and pipeline? - The company continues to see momentum in the payer business, with an increase in covered lives and ongoing discussions with potential new payers [41][46] Question: How should we think about EBITDA cadence throughout the year? - Most of the adjusted EBITDA loss is expected in the first half of the year, with a transition to profitability in the second half as efficiency measures take effect [68]

Summary of DocGo Conference Call Company Overview - **Company Name**: DocGo - **Industry**: Mobile health and medical transportation services - **Stock Symbol**: DCGO (NASDAQ) - **Geographic Presence**: United States and United Kingdom - **Core Services**: Medical transportation, care in the home, remote patient monitoring, and technology-driven mobile healthcare solutions [1][2][3] Key Points and Arguments Business Model and Services - DocGo operates a tech-driven mobile health platform that includes ambulance services, medical transportation management, and home care services [2][4] - The company aims to deliver healthcare at any address, providing a turnkey solution for hospitals and facilities that prefer to outsource their transportation needs [4][5] - The use of "upskilled clinicians" allows for more efficient care delivery, utilizing qualified personnel for tasks that are often performed by overqualified individuals [5][6] Financial Performance - In 2023, DocGo's revenues peaked at over $600 million, largely due to non-recurring revenue from migrant-related services [15] - Projected revenue for 2025 is approximately $320 million, indicating a significant drop due to the transition away from non-core services [15] - Core medical transportation revenue has grown from $48 million in 2019 to over $200 million in 2023, demonstrating steady growth despite overall revenue fluctuations [16] Recent Developments - The acquisition of SteadyMD enhances DocGo's telehealth capabilities and expands its virtual care network across all 50 states [10][11] - The company has a strong balance sheet, with a cash balance of approximately $95 million and a focus on both organic and inorganic growth strategies [20][46] Market Position and Strategy - DocGo operates in a fragmented market with over 10,000 ambulance providers in the U.S., positioning itself as a scalable solution provider [37] - The company emphasizes vertical integration and a competitive technology advantage, which are critical for maintaining its market position [47][40] - Partnerships with health plan providers allow DocGo to reach patients who are delinquent in receiving necessary care, thereby increasing access and reducing overall healthcare costs [32][25] Challenges and Future Outlook - The company faces challenges related to accounts receivable, particularly from municipal contracts, but has successfully collected 96% of outstanding invoices [49] - The new mayoral administration in New York City may present both opportunities and risks, but DocGo's existing contracts with health and hospital systems are expected to continue [50][51] - The focus remains on closing care gaps and providing efficient healthcare solutions to prevent hospital readmissions and manage chronic diseases [22][24] Additional Important Information - DocGo's mobile health segment is expected to conduct over 150,000 home visits in 2025, reflecting the growing demand for home-based healthcare services [28] - The company is actively looking for acquisition opportunities in the healthcare sector, viewing current market conditions as favorable for growth [44][45] - Leadership includes experienced professionals from both healthcare and general management backgrounds, contributing to a well-rounded management team [47][39]

Summary of the Conference Call Company and Industry Overview - The conference is part of the 23rd annual Morgan Stanley Healthcare Conference, focusing on the healthcare industry and innovations in home-based care [2][3] - The company discussed is DocGo, a medical transportation and mobile health provider, which has been innovating in the medical transportation space for over 10 years [4][5] Key Points and Arguments Mobile Health Growth - DocGo has seen significant growth in the mobile health segment, particularly in coordinating care for high-utilizing members through partnerships with insurance companies [4][5] - The company has expanded its reach from serving 2,000 patients to nearly a million patients across the New York tri-state area and California [6][8] - On average, DocGo closes almost two care gaps per home visit, with some visits closing up to six gaps [6][8] Technology Integration - The tech stack developed by DocGo is crucial for efficient home-based medical care, allowing licensed practical nurses (LPNs) and medical assistants to provide care under the direction of primary care providers [10][11] - Integration with electronic health record (EHR) systems like Epic enhances coordination and efficiency in patient care [11] Revenue and Contract Stability - DocGo's contracts in the transportation segment typically last three to five years and are described as "sticky," indicating high customer retention [13][14] - The company is transitioning from episodic contracts with municipal governments to more sustainable, population health-focused contracts with payers [15] Labor and Inflation Management - Staffing is a significant challenge, with 800 open roles to fill, but the company maintains a strong reputation as a desirable workplace [16][18] - Inflationary pressures are minimal, with fuel costs decreasing and existing vehicles owned or procured under favorable terms [17] Payer Opportunities - DocGo works primarily with managed care, Medicaid, and Medicare Advantage plans, focusing on the dual special needs population, which shows higher engagement rates [20][21] - The company aims to keep patients out of hospitals, aligning with value-based care models that incentivize health plans to manage costs effectively [23][24] M&A Strategy - DocGo is looking for M&A opportunities that add capabilities or expand geographic reach, particularly in underserved areas [26][27] - The medical transportation market is estimated at $10 billion, with DocGo currently capturing around $225 million, indicating significant growth potential [49] Capital Allocation - The company prioritizes organic growth, staff training, and M&A opportunities while maintaining a strong balance sheet with over $100 million in cash [30][32][33] Market Expansion - DocGo expands into new markets based on demand from existing customers, ensuring they have anchor clients before entering new regions [37][38] Go-to-Market Strategy - The sales cycle for new customers can range from 6 to 18 months, with existing customers typically resulting in faster expansions [42][43] Telehealth Perspective - While telehealth is recognized as a valuable service, DocGo emphasizes the necessity of in-person care for certain medical needs, positioning itself uniquely in the market [54][56] Other Important Insights - The company has a high Net Promoter Score of over 90, indicating strong patient satisfaction [47][48] - The medical transportation segment is increasingly recognized as vital for patient flow management within hospital systems [51][52]

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $96 million, down from $192.1 million in Q1 2024, primarily due to the decline in the government vertical, especially in migrant-related projects [19] - The company recorded a net loss of $11.1 million in Q1 2025 compared to a net income of $10.6 million in Q1 2024 [20] - Adjusted EBITDA for Q1 2025 was a loss of $3.9 million, down from an adjusted EBITDA of $24.1 million in Q1 2024 [21] - The adjusted gross margin for Q1 2025 was 32.1%, compared to 35% in Q1 2024 [21] Business Line Data and Key Metrics Changes - Mobile health revenue for Q1 2025 was $45.2 million, down from $143.9 million in Q1 2024, driven by the anticipated wind down of migrant revenues [20] - Medical transportation services revenue increased to $50.8 million in Q1 2025 from $48.2 million in Q1 2024, supported by growth in several markets [20] - The medical transportation business is expected to have an adjusted EBITDA of greater than $15 million in 2025, with projected total transports reaching approximately 575,000 by the end of 2025 [10] Market Data and Key Metrics Changes - The company has seen substantial growth in its payer and provider vertical, exceeding 900,000 assigned lives, up from 700,000 just a quarter ago [11] - The number of care gap closure and transitional care management visits is projected to grow from approximately 4,400 in Q4 2024 to over 11,500 in Q4 2025 [12] Company Strategy and Development Direction - The company has removed its government population health vertical from its 2025 guidance due to ongoing policy changes and budget cuts, leading to substantial uncertainty [6] - The focus is on building the company around innovative solutions for payers, providers, and health systems, particularly in mobile health and medical transportation [9] - Cost-cutting measures have been initiated, with SG&A reduced by approximately $3.1 million sequentially in Q1 2025, while the company plans to aggressively cut SG&A over the next several quarters [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory of the medical transportation and payer/provider verticals despite the challenges in the government sector [9] - The company anticipates positive cash flow from operations and expects to exit the year with over $110 million in cash, despite projecting a consolidated adjusted EBITDA loss for the year [17] - Management highlighted the importance of their technology platform in securing new contracts and improving patient outcomes [11] Other Important Information - The company has initiated a stock buyback program, repurchasing nearly 2 million shares for approximately $5.8 million in Q1 2025 [27] - The balance sheet remains healthy, with expectations for improved cash flow from operations as accounts receivable from migrant programs are collected [26] Q&A Session Summary Question: What is the expected government revenue for the remainder of the year? - Management clarified that government population health revenues have been removed from guidance, and any new deployments will be reported separately as upside [31][32] Question: How is the company balancing SG&A cuts with staffing for future government engagements? - Management indicated they are restructuring shared services for savings while reinvesting in growing parts of the business to prepare for future growth [33][34] Question: What is the demand outlook for the payer business? - Management noted healthy demand in the payer segment, with proactive healthcare services aimed at reducing medical loss ratios and improving quality metrics [39][41] Question: What caused the revenue miss in Q1? - The revenue miss was attributed to the government vertical, with delays in contract launches and RFP responses impacting expected revenues [48][55] Question: What is the margin profile of the migrant-related revenue? - The margins on the migrant program were about 34%, consistent with previous quarters, while the non-migrant mobile health segment had higher margins [78] Question: Are there risks from tariffs on medical equipment? - Management acknowledged potential tariff impacts on fleet procurement and maintenance but expressed confidence in their fleet management capabilities [80]